The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV
Lisa O’Brien, Nathan Shaffer, Nalinee Sangrujee & Taiwo O Abimbola
Volume 92, Number 3, March 2014, 162-170
Table 3. Incremental costa per woman of Option B+b relative to Option Bc over 5 years postpartum
|Breastfeeding status and duration||CD4+ count 350–500 cells/µl
||CD4+ count > 500 cells/µl
|Total cost Option B+||Total cost Option B||Incremental cost||Total cost Option B+||Total cost Option B||Incremental cost|
a All costs are given in 2011 United States dollars.
b Option B+ comprises a triple antiretroviral (ARV) regimen initiated during pregnancy and continued for life.
c Option B comprises a maternal triple ARV regimen, typically consisting of the recommended first-line antiretroviral therapy (ART), during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.
Note: Within each CD4+ cell count stratum, the time to ART treatment eligibility was the same regardless of breastfeeding duration; however, the time in treatment varied across breastfeeding duration categories.